Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy

  • Systematic Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

  • 3 Altmetric

Abstract

Nurses’s support of patients needs an evidence base as much as that of specialists management. However, some more practical aspects need specific questions that are not addressed in medical societies’ recommendations. Our objective was to investigate the effect of Janus kinase inhibitors (jakinibs) on efficacy, safety, infections, cardiovascular risk, vaccination, pregnancy and lactation, interactions, surgery, and switch in adult patients with rheumatic diseases. We used the methodology for rapid reviews. Medline was searched for systematic reviews of randomised clinical trials and longitudinal observational studies reporting on the target aspects, without limits, yielding 540 titles, of which 70 articles were selected for detailed reading after the screening of title and abstract. In the case of no systematic review being published on a specific question, we resorted to the information provided by primary studies. The efficacy and safety profiles are similar to that of TNF-inhibitors to which they are compared in most studies; however, there is an increased risk of herpes zoster infections with jakinibs. The evidence on pregnancy, surgery and switches between jakinibs is very limited, although, so far, there are no major issues to inform patients about or to implement specific measures. In general, evidence to support nursing management in patients being treated with jakinibs is of moderate quality and scarce, ought to the recent incursion of jakinibs as a treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The protocols and bibliographic databases are available upon reasonable request.

References

  1. Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M (2021) Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells. https://doi.org/10.3390/cells10020323

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hernández-Flórez D, Valor L (2016) Protein-kinase inhibitors: a new treatment pathway for autoimmune and inflammatory diseases? Reumatol Clin 12(2):91–99. https://doi.org/10.1016/j.reuma.2015.06.004

    Article  PubMed  Google Scholar 

  3. Serra López-Matencio JM, Morell Baladrón A, Castañeda S (2019) JAK-STAT inhibitors for the treatment of immunomediated diseases. Med Clin 152(9):353–360. https://doi.org/10.1016/j.medcli.2018.10.020

    Article  Google Scholar 

  4. Fabbro D (2015) 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol 87(5):766–775. https://doi.org/10.1124/mol.114.095489

    Article  PubMed  CAS  Google Scholar 

  5. Jegatheeswaran J, Turk M, Pope JE (2019) Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy 11(8):737–754. https://doi.org/10.2217/imt-2018-0178

    Article  PubMed  CAS  Google Scholar 

  6. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80(1):71–87. https://doi.org/10.1136/annrheumdis-2020-218398

    Article  PubMed  CAS  Google Scholar 

  7. Bech B, Primdahl J, van Tubergen A, Voshaar M, Zangi HA, Barbosa L, Boström C, Boteva B, Carubbi F, Fayet F, Ferreira RJO, Hoeper K, Kocher A, Kukkurainen ML, Lion V, Minnock P, Moretti A, Ndosi M, Pavic Nikolic M, Schirmer M, Smucrova H, de la Torre-Aboki J, Waite-Jones J, van Eijk-Hustings Y (2020) 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis 79(1):61–68. https://doi.org/10.1136/annrheumdis-2019-215458

    Article  PubMed  Google Scholar 

  8. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655

    Article  PubMed  CAS  Google Scholar 

  9. Louthrenoo W, Kasitanon N, Katchamart W, Aiewruengsurat D, Chevaisrakul P, Chiowchanwisawakit P, Dechanuwong P, Hanvivadhanakul P, Mahakkanukrauh A, Manavathongchai S, Muangchan C, Narongroeknawin P, Phumethum V, Siripaitoon B, Suesuwan A, Suwannaroj S, Uea-Areewongsa P, Ukritchon S, Asavatanabodee P, Koolvisoot A, Nanagara R, Totemchokchyakarn K, Nuntirooj K, Kitumnuaypong T (2017) 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Int J Rheum Dis 20(9):1166–1184. https://doi.org/10.1111/1756-185x.13130

    Article  PubMed  Google Scholar 

  10. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A (2021) Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol 130:13–22. https://doi.org/10.1016/j.jclinepi.2020.10.007

    Article  PubMed  Google Scholar 

  11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

    Article  PubMed  PubMed Central  Google Scholar 

  12. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. https://doi.org/10.1136/bmj.j4008

    Article  PubMed  PubMed Central  Google Scholar 

  13. Higgins J, Savović J, Page M, Elbers R, Sterne J (2022) Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 63 (updated February 2022), cochrane. Wiley

    Google Scholar 

  14. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Jan 2021

  15. Bae SC, Lee YH (2019) Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol 78(6):559–567. https://doi.org/10.1007/s00393-018-0531-5

    Article  PubMed  CAS  Google Scholar 

  16. Zhang X, Liang F, Yin X, Xiao X, Shi P, Wei D, Yao L, Wang Q, Chen Y (2014) Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis. Clin Rheumatol 33(2):165–173. https://doi.org/10.1007/s10067-013-2452-7

    Article  PubMed  CAS  Google Scholar 

  17. Harrington R, Al Nokhatha SA, Conway R (2020) JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res 13:519–531. https://doi.org/10.2147/jir.S219586

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWJ, Burmester GR, de Wit M, Falzon L, Landewé R (2020) Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 79(6):744–759. https://doi.org/10.1136/annrheumdis-2019-216656

    Article  PubMed  CAS  Google Scholar 

  19. Wang F, Sun L, Wang S, Davis JM 3rd, Matteson EL, Murad MH, Luo F, Vassallo R (2020) Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 95(7):1404–1419. https://doi.org/10.1016/j.mayocp.2020.01.039

    Article  PubMed  CAS  Google Scholar 

  20. Pham PA, Dressler C, Eisert L, Nast A, Werner RN (2019) Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatol Int 39(4):605–618. https://doi.org/10.1007/s00296-019-04244-5

    Article  PubMed  CAS  Google Scholar 

  21. Khoo JK, Barnes H, Key S, Glaspole IN, Östör AJ (2020) Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford) 59(9):2217–2225. https://doi.org/10.1093/rheumatology/keaa117

    Article  CAS  Google Scholar 

  22. Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, VandeCasteele N, Khanna R, Panaccione R, Feagan BG, Jairath V (2019) Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 50(1):5–23. https://doi.org/10.1111/apt.15297

    Article  PubMed  CAS  Google Scholar 

  23. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ (2014) Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 73(5):871–882. https://doi.org/10.1136/annrheumdis-2012-203116

    Article  PubMed  CAS  Google Scholar 

  24. Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JW, Burmester GR, de Wit M, Falzon L, Landewé R (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79(6):760–770. https://doi.org/10.1136/annrheumdis-2019-216653

    Article  PubMed  CAS  Google Scholar 

  25. Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58(10):1755–1766. https://doi.org/10.1093/rheumatology/kez087

    Article  CAS  Google Scholar 

  26. Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF (2019) A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 81(1):102–110. https://doi.org/10.1016/j.jaad.2019.03.017

    Article  PubMed  Google Scholar 

  27. Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB (2018) A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol 45(6):733–744. https://doi.org/10.3899/jrheum.170710

    Article  PubMed  CAS  Google Scholar 

  28. Huang F, Luo ZC (2018) Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. BioDrugs 32(5):415–423. https://doi.org/10.1007/s40259-018-0304-3

    Article  PubMed  CAS  Google Scholar 

  29. Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78(8):1048–1054. https://doi.org/10.1136/annrheumdis-2018-214846

    Article  PubMed  CAS  Google Scholar 

  30. CIMA-AEMPS Baricitinib (2022) Ficha técnica o resumen de las caraterísticas del producto. https://cima.aemps.es/cima/pdfs/ft/1161170002/FT_1161170002.pdf. Accessed 08 Feb 2022

  31. CIMA-AEMPS Filgofitinib (2022) Ficha técnica o resumen de las características del producto. https://cima.aemps.es/cima/pdfs/es/ft/1201480003/FT_1201480003.pdf. Accessed 08 Feb 2022

  32. CIMA-AEMPS Tofacitinib. Ficha técnica o resumen de las características del producto. https://cima.aemps.es/cima/pdfs/es/ft/1171178003/FT_1171178003.pdf. Accessed Apr 2021

  33. AEMPS (2021) Xeljanz (tofacitinib): nuevas precauciones de uso. https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2021-seguridad-1/xeljanz-tofacitinib-nuevas-precauciones-de-uso/. Accessed 15 Feb 2022, 2022

  34. CIMA-AEMPS Upadacitinib. Ficha técnica o resumen de las características del producto. https://cima.aemps.es/cima/pdfs/es/ft/1191404001/FT_1191404001.pdf. Accessed Apr 2021

  35. Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, Gewurz-Singer O, Giles JT, Johnson B, Lee S, Mandl LA, Mont MA, Sculco P, Sporer S, Stryker L, Turgunbaev M, Brause B, Chen AF, Gililland J, Goodman M, Hurley-Rosenblatt A, Kirou K, Losina E, MacKenzie R, Michaud K, Mikuls T, Russell L, Sah A, Miller AS, Singh JA, Yates A (2017) 2017 American college of rheumatology/american association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. J Arthroplasty 32(9):2628–2638. https://doi.org/10.1016/j.arth.2017.05.001

    Article  PubMed  Google Scholar 

  36. Goodman SM, George MD (2020) Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases? RMD Open. https://doi.org/10.1136/rmdopen-2020-001214

    Article  PubMed  PubMed Central  Google Scholar 

  37. Agrawal M, Kim ES, Colombel JF (2020) JAK inhibitors safety in ulcerative colitis: practical implications. J Crohns Colitis 14(Supplement_2):S755-s760. https://doi.org/10.1093/ecco-jcc/jjaa017

    Article  PubMed  PubMed Central  Google Scholar 

  38. Chang S, Hudesman D (2020) First-line biologics or small molecules in inflammatory bowel disease: a practical guide for the clinician. Curr Gastroenterol Rep 22(2):7. https://doi.org/10.1007/s11894-020-0745-y

    Article  PubMed  Google Scholar 

  39. Förger F, Villiger PM (2016) Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol 12(9):937–944. https://doi.org/10.1080/1744666x.2016.1184973

    Article  PubMed  Google Scholar 

  40. Gerosa M, Argolini LM, Artusi C, Chighizola CB (2018) The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 11(10):987–998. https://doi.org/10.1080/17512433.2018.1525293

    Article  PubMed  CAS  Google Scholar 

  41. Gisbert JP, Chaparro M (2020) Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs 80(11):1085–1100. https://doi.org/10.1007/s40265-020-01346-4

    Article  PubMed  CAS  Google Scholar 

  42. Laube R, Paramsothy S, Leong RW (2021) Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf 20(3):275–292. https://doi.org/10.1080/14740338.2021.1873948

    Article  PubMed  Google Scholar 

  43. Picardo S, Seow CH (2019) A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy. Drugs 79(10):1053–1063. https://doi.org/10.1007/s40265-019-01141-w

    Article  PubMed  Google Scholar 

  44. Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, Viola A, Canofari C, Perricone R (2019) Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev 18(7):706–713. https://doi.org/10.1016/j.autrev.2019.05.007

    Article  PubMed  Google Scholar 

  45. GötestamSkorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810. https://doi.org/10.1136/annrheumdis-2015-208840

    Article  CAS  Google Scholar 

  46. Levy RA, de Jesús GR, de Jesús NR, Klumb EM (2016) Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 15(10):955–963. https://doi.org/10.1016/j.autrev.2016.07.014

    Article  PubMed  Google Scholar 

  47. Saavedra MA, Romo-Rodríguez R, Gutiérrez-Ureña SR, Miranda-Hernández D, Hernández-Cruz LI, Jara LJ (2018) Targeted drugs in spondyloarthritis during pregnancy and lactation. Pharmacol Res 136:21–28. https://doi.org/10.1016/j.phrs.2018.08.009

    Article  PubMed  CAS  Google Scholar 

  48. Begley R, Anderson K, Watkins TR, Weng W, Ampaw L, Qin A, Kearney BP, Mathias A (2021) Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev 10(4):376–383. https://doi.org/10.1002/cpdd.870

    Article  PubMed  CAS  Google Scholar 

  49. Mohamed MF, Minocha M, Trueman S, Feng T, Enejosa J, Fisniku O, Othman AA (2021) Characterization of the effect of upadacitinib on the pharmacokinetics of bupropion, a sensitive cytochrome P450 2B6 probe substrate. Clin Pharmacol Drug Dev 10(3):299–306. https://doi.org/10.1002/cpdd.844

    Article  PubMed  CAS  Google Scholar 

  50. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, BirruTalabi M, Turgunbaev M, Turner A, D’Anci KE (2020) 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 72(4):461–488. https://doi.org/10.1002/acr.24130

    Article  Google Scholar 

  51. Lamba M, Wang R, Fletcher T, Alvey C, Jt K, Stock TC (2016) Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol 56(11):1362–1371. https://doi.org/10.1002/jcph.734

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759–773. https://doi.org/10.1124/dmd.113.054940

    Article  PubMed  CAS  Google Scholar 

  53. Cohen S, Zwillich SH, Chow V, Labadie RR, Wilkinson B (2010) Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 69(2):143–151. https://doi.org/10.1111/j.1365-2125.2009.03570.x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Yu B, Wang X, Yang Y, Lu C, Hu W, Zhang X (2021) Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects. Int J Clin Pharmacol Ther 59(4):343–352. https://doi.org/10.5414/cp203751

    Article  PubMed  CAS  Google Scholar 

  55. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54(12):1354–1361. https://doi.org/10.1002/jcph.354

    Article  PubMed  CAS  Google Scholar 

  56. Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA (2017) Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol 83(10):2242–2248. https://doi.org/10.1111/bcp.13329

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Cao YJ, Sawamoto T, Valluri U, Cho K, Lewand M, Swan S, Lasseter K, Matson M, Holman J Jr, Keirns J, Zhu T (2016) Pharmacokinetics, pharmacodynamics, and safety of ASP015K (Peficitinib), a New Janus kinase inhibitor, in healthy subjects. Clin Pharmacol Drug Dev 5(6):435–449. https://doi.org/10.1002/cpdd.273

    Article  PubMed  CAS  Google Scholar 

  58. Anderson K, Zheng H, Kotecha M, Cuvin J, Scott B, Sharma S, Qin AR, Namour F, Xin Y (2019) The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev 8(5):585–594. https://doi.org/10.1002/cpdd.659

    Article  PubMed  CAS  Google Scholar 

  59. Ibrahim SSA, Salama MA, Selima E, Shehata RR (2020) Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-kappaB signaling pathways. Life Sci 260:118261. https://doi.org/10.1016/j.lfs.2020.118261

    Article  PubMed  CAS  Google Scholar 

  60. Walton A, Paik J, Quebe A, Kannowski CL, Choong C, Anderson S, Owensby JK (2021) Frequency of prescription claims for drugs that may interact with janus kinase inhibitors among patients with rheumatoid arthritis in the US. Rheumatol Ther 8(1):599–607. https://doi.org/10.1007/s40744-020-00275-8

    Article  PubMed  PubMed Central  Google Scholar 

  61. Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R (2018) Effect of glucocorticoids on the clinical and radiographic efficacy of tofacitinib in patients with rheumatoid arthritis: a posthoc analysis of data from 6 phase III studies. J Rheumatol 45(2):177–187. https://doi.org/10.3899/jrheum.170486

    Article  PubMed  CAS  Google Scholar 

  62. Chen Y, Gong FY, Li ZJ, Gong Z, Zhou Z, Ma SY, Gao XM (2017) A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Sci Rep 7(1):6779. https://doi.org/10.1038/s41598-017-07261-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Nam SH, Oh JS, Hong S, Shim TS, Lee CK, Yoo B, Kim YG (2020) Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. Joint Bone Spine 87(5):475–479. https://doi.org/10.1016/j.jbspin.2020.04.010

    Article  PubMed  CAS  Google Scholar 

  64. Mohamed MF, Trueman S, Feng T, Friedman A, Othman AA (2019) The JAK1 inhibitor upadacitinib has no effect on the pharmacokinetics of levonorgestrel and ethinylestradiol: a study in healthy female subjects. J Clin Pharmacol 59(4):510–516. https://doi.org/10.1002/jcph.1350

    Article  PubMed  CAS  Google Scholar 

  65. Retuerto M, Trujillo E, Valero C, Fernandez-Espartero C, Soleto CY, Garcia-Valle A, Aurrecoechea E, Garijo M, Lopez A, Loricera J, Pablos JL (2021) Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study. Clin Exp Rheumatol 39(3):453–455

    Article  Google Scholar 

  66. Alhumaid S, Al Mutair A, Al Alawi Z, Alsuliman M, Ahmed GY, Rabaan AA, Al-Tawfiq JA, Al-Omari A (2021) Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review. Antimicrob Resist Infect Control 10(1):86. https://doi.org/10.1186/s13756-021-00957-0

    Article  PubMed  PubMed Central  Google Scholar 

  67. Hamel C, Michaud A, Thuku M, Skidmore B, Stevens A, Nussbaumer-Streit B, Garritty C (2021) Defining Rapid Reviews: a systematic scoping review and thematic analysis of definitions and defining characteristics of rapid reviews. J Clin Epidemiol 129:74–85. https://doi.org/10.1016/j.jclinepi.2020.09.041

    Article  PubMed  Google Scholar 

Download references

Funding

The study was funded by Openreuma through a non-restrictive grant from Galapagos.

Author information

Authors and Affiliations

  1. Openreuma, Madrid, Spain

    Laura Lorena Castiblanco

  2. Institute of Musculoskeletal Health (Inmusc), Calle de Méndez Álvaro, 20, 28045, Madrid, Spain

    María Jesús García de Yébenes & Loreto Carmona

  3. University Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

    Jose María Martín Martín

Authors
  1. Laura Lorena Castiblanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Jesús García de Yébenes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose María Martín Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Loreto Carmona
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LLC conceived the study, participated in its design and coordination, and critically revised the manuscript. LLC y LC had full access to all of the data collection, analysis, interpretation and drafted the manuscript. LLC, LC, MJGY and JMMM were study investigators and contributed to the process of data collection. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Loreto Carmona.

Ethics declarations

Conflict of interest

JMMM, LLC, MJGY and LC have no conflicts of interest.

Consent for publication

Not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 189 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castiblanco, L.L., García de Yébenes, M.J., Martín Martín, J.M. et al. Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy. Rheumatol Int 42, 2125–2133 (2022). https://doi.org/10.1007/s00296-022-05185-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-022-05185-2

Keywords

Search

Navigation